Highlights of This Issue 2077

SMALL MOLECULE THERAPEUTICS

2079 Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Krishna B. Singh, Xinhua Ji, and Shivendra V. Singh

2091 Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439
Yongkang Zou, Zhi Qi, Weilong Guo, Lizhen Zhang, Marcus Ruscetti, Tanu Shenoy, Ningshu Liu, and Hong Wu

2100 Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study
Li Peng, Wenting Shang, Pengyu Guo, Kunshan He, Honglei Wang, Ziyu Han, Hongmei Jiang, Jie Tian, Kun Wang, and Wanhai Xu

2112 Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms
Aaron J. Scott, John J. Arcaroli, Stacey M. Bagby, Rachel Yahna, Kendra M. Huber, Natalie J. Serkova, Anna Nguyen, Jihye Kim, Andrew Thooburn, Jon Vogel, Kevin S. Quackenbush, Anna Capasso, Anna Schreiber, Patrick Blatchford, Peter J. Krauck, Todd M. Pitts, S. Gail Eckhardt, and Wells A. Messersmith

2123 Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition
Alexandria N. Young, Denise Herrera, Andrew C. Huntsman, Melissa A. Korkmaz, Daniel D. Lantvit, Samirasha Mazumder, Shamalatha Kolli, Christopher C. Cosso, Salane King, Hongyan Wang, Steven M. Swanson, A. Douglas Kinghorn, Xiaoli Zhang, Mitch A. Phelps, Leslie N. Aldrich, James R. Fuchs, and Joanna E. Burdette

2136 Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer
Megan Buechel, Anindyaa Dey, Shalendendra Kumar Dhar Dwivedi, Aleia Crim, Kai Ding, Roy Zhang, Priyabrata Mukherjee, Kathleen N. Moore, Liangxin Cao, Arthur Bramstrom, Marla Weetall, John Baird, and Ramesh Bhattacharyya

2144 Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Hongmei Jiang, Mai Xu, Lin Li, Patrick Grierson, Paarth Dodhiawala, Maureen Highkin, Daoxiang Zhang, Qiong Li, Andrea Wang-Gillam, and Kian-Huat Lim

2156 Auranofin Enhances Ibrutinib’s Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Jing Hu, Huijuan Zhang, Mengru Cao, Li Wang, Shuhong Wu, and Bingliang Fang

LARGE MOLECULE THERAPEUTICS

2164 Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Zhizhou Wu, Hong-Fen Guo, Hong Xu, and Nai-Kong V. Cheung

2176 Antitumor Activity of MED13276 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2187</td>
<td>A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells</td>
<td>Hisatsugu Maekawa, Hinoyuki Miyoshi, Tadayoshi Yamauta, Yoshiro Itatani, Kenji Kawada, Yoshiharu Sakai, and M. Mark Taketo</td>
</tr>
<tr>
<td>2197</td>
<td>Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer</td>
<td>Alan P. Lombard, Liangren Liu, Vito Cucchiara, Chenglei Liu, Cameron M. Armstrong, Ruining Zhao, Joy C. Yang, Wei Lou, Christopher P. Evans, and Allen C. Gao</td>
</tr>
<tr>
<td>2206</td>
<td>Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks</td>
<td>Aashish Soni, Fanghua Li, You Wang, Martha Grabos, Lisa Marie Krieger, Shipra Chaudhary, Mohammad Sharif Mortoga Hasan, Mansoor Ahmed, C. Norman Coleman, Beverly A. Teicher, Richard L. Piekarz, Dian Wang, and George E. Iliakis</td>
</tr>
<tr>
<td>2217</td>
<td>Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer</td>
<td>Hitoshi Sase, Yoshito Nakashima, Satoshi Aida, Kana Horiguchi-Takei, Nukinori Akiyama, Yoshihiko Fujii, Kiyoko Sakata, Yoshikuni Mio, Masahiro Aoki, and Nobuya Ishii</td>
</tr>
<tr>
<td>2226</td>
<td>Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death</td>
<td>Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, and Reshmi Parameswaran</td>
</tr>
<tr>
<td>2238</td>
<td>Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer</td>
<td>Hung-Chih Hsu, Nina Lapke, Chuang-Wei Wang, Pei-Yi Lin, Jeng Fu You, Chien Yuh Yeh, Wen-Sy Tsai, Hsin Yuan Hung, Sum-Fu Chiang, Hua-Chien Chen, Shu-Jen Chen, An Hsu, and Tsai Sheng Yang</td>
</tr>
<tr>
<td>2248</td>
<td>Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105</td>
<td>Yingmiao Liu, Mark D. Starr, John C. Brady, Christel Rushing, Herbert Pang, Bonne Adams, Delia Alvarez, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon</td>
</tr>
<tr>
<td>2257</td>
<td>CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer</td>
<td>Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Aik-Choon Tan, Hiroshi Mizuuchi, Leslie Roseboom, Kim Ellison, Christopher J. Rivard, Tetuya Mitsudomi, and Fred R. Hirsch</td>
</tr>
</tbody>
</table>

**RETRACTIONS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2266</td>
<td>Retraction: Apoptosis-Inducing Effect of Erlotinib Is Potentiated by 3,3'-Diindolylmethane In Vitro and In Vivo Using an Orthotopic Model of Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td>2267</td>
<td>Retraction: Therapeutic Intervention of Experimental Breast Cancer Bone Metastasis by Indole-3-carbinol in SCID-human Mouse Model</td>
<td></td>
</tr>
<tr>
<td>2268</td>
<td>Retraction: Downregulation of Notch-1 Contributes to Cell Growth Inhibition and Apoptosis in Pancreatic Cancer Cells</td>
<td></td>
</tr>
</tbody>
</table>

*AC icon indicates AuthorChoice*

For more information please visit www.aacrjournals.org
ABOUT THE COVER

Antibody–drug conjugates (ADC) are a new class of therapeutics that combine the high specificity and affinity of antibodies to the strong cytotoxic activity of small molecules. Prostate-specific membrane antigen (PSMA) is a well-characterized tumor-associated antigen for prostate cancer. The image shows homogeneous and strongly positive PSMA staining, as determined by immunohistochemistry, in the LNCaP prostate cancer xenograft. Cho, Zammarchi, and colleagues demonstrate that MEDI3726, a PBD-based PSMA-targeting ADC currently in a phase I clinical trial, has potent and specific cytotoxicity in a panel of PSMA-positive prostate cancer cell lines and robust and durable antitumor activity against prostate cancer cell line xenografts and patient-derived xenograft models.
Molecular Cancer Therapeutics

17 (10)

Mol Cancer Ther 2018;17:2077-2268.

Updated version

Access the most recent version of this article at:
http://mct.aacrjournals.org/content/17/10

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/17/10. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.